Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
Natera and Aveta Biomics announced a strategic partnership to support Aveta’s global Phase 3 registrational trial of APG-157 in head and neck cancer. Signatera will be used to evaluate molecular response and detect molecular residual disease (MRD) across approximately 826 patients enrolled in the study.
Key figures
- Trial enrollment
- 826
- Global annual incidence hnc
- 950000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.